• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

    2/14/24 4:26:22 PM ET
    $ADXS
    Major Pharmaceuticals
    Health Care
    Get the next $ADXS alert in real time by email
    SC 13G/A 1 tm245846d20_sc13ga.htm SCHDULE 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    AYALA PHARMACEUTICALS, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)

     

     

    007624307
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 007624307

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    211,014 (1) 

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    211,014 (1) 

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    211,014 (1) 

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    1.9%(2) 

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

           

     

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common shares (“Common Stock”) is comprised of (a) 123,562 shares of Common Stock and (b) 87,452 shares of Common Stock issuable upon exercise of certain pre-funded warrants (the “Warrants”), which, in each case, are owned by certain private investment vehicles managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles, as well as by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (2) Percentage based on: (i) 10,751,792 shares of Common Stock outstanding as of November 11, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the SEC on November 20, 2023 (the “Form 10-Q”), plus (ii) 87,452 shares of Common Stock issuable upon exercise of the Warrants.

     

     

     

    CUSIP No. 007624307

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    211,014 (3) 

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    211,014 (3) 

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    211,014 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    1.9%(4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

           

     

     

    (3) Jeremy C. Green’s beneficial ownership of the Common Stock is comprised of (a) 123,562 shares of Common Stock and (b) 87,452 shares of Common Stock issuable upon exercise of the Warrants, which, in each case, are owned by certain private investment vehicles managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles, as well as by Mr. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (4) Percentage based on: (i) 10,751,792 shares of Common Stock outstanding as of November 11, 2023, as reported by the Issuer in its Form 10-Q, plus (ii) 87,452 shares of Common Stock issuable upon exercise of the Warrants.

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Ayala Pharmaceuticals, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    9 Deer Park Drive, Suite K-1

    Monmouth Junction, NJ 08852

     

    Item 2.

     

    (a)Names of Persons Filing

     

    Redmile Group, LLC
    Jeremy C. Green

     

    (b)Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC (NY Office)
    45 W. 27th Street, Floor 11
    New York, NY 10001

     

    (c)Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

    (d)Title of Class of Securities

     

    Common Stock, $0.001 par value

     

    (e)CUSIP Number

     

    007624307

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

     

     

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e)x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g)x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Redmile Group, LLC – 211,014 *
    Jeremy C. Green – 211,014 *

     

    (b)Percent of class:

     

    Redmile Group, LLC – 1.9%****
    Jeremy C. Green – 1.9%****

     

    (c)Number of shares as to which Redmile Group, LLC has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    211,014 *

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    211,014 *

     

     

     

     

    Number of shares as to which Jeremy C. Green has:

     

    (i)Sole power to vote or to direct the vote:

     

    0

     

    (ii)Shared power to vote or to direct the vote:

     

    211,014 *

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    211,014 *

     

     

    *Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of the Issuer’s Common Stock is comprised of: (a) 123,562 shares of Common Stock and (b) 87,452 shares of Common Stock issuable upon exercise of the Warrants, in each case, owned by certain private investment vehicles managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles, as well as by Mr. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

    **Percentage based on: (i) 10,751,792 shares of Common Stock outstanding as of November 11, 2023, as reported by the Issuer in its Form 10-Q, plus (ii) 87,452 shares of Common Stock issuable upon exercise of the Warrants.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8.Identification and Classification of Members of the Group.

     

    N/A.

     

    Item 9.Notice of Dissolution of Group.

     

    N/A.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

    SIGNATURE

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

     

    Redmile Group, LLC

     

         
      By:   /s/ Jeremy C. Green
         

    Name: Jeremy C. Green

    Title: Managing Member

     

     

          /s/ Jeremy C. Green
         

    Jeremy C. Green

     

     

     

    Get the next $ADXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADXS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Advaxis, Inc.

      15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      5/9/24 4:05:37 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)

      10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/26/24 5:03:01 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)

      8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)

      4/19/24 7:50:34 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    $ADXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

      Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

      1/29/25 9:22:00 AM ET
      $ADXS
      $OSTX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations

      MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Comp

      5/9/24 4:10:00 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

      MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (NASDAQ:IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments. "We are pleased that AL102 will now be advanced by the highly experienced team at Immunome," said Ken Berlin, President and

      3/26/24 8:00:00 AM ET
      $ADXS
      $IMNM
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ADXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

      SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

      2/14/24 4:26:22 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Advaxis, Inc. (Amendment)

      SC 13D/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

      2/12/24 11:58:05 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Advaxis, Inc. (Amendment)

      SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)

      2/12/24 8:27:51 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    $ADXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Israel Biotech Fund I, L.P.

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      3/6/24 7:13:01 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Israel Biotech Fund I, L.P. exercised 27,847,159 shares at a strike of $0.40 and covered exercise/tax liability with 5,294,486 shares (SEC Form 4)

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      2/12/24 2:16:21 PM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Israel Biotech Fund I, L.P.

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      11/21/23 9:04:41 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    $ADXS
    Leadership Updates

    Live Leadership Updates

    See more
    • OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

      Consolidates ownership of listeria monocytogenes-based immunotherapy IP Eliminates milestone payments and reduces future royalty obligations relating to OST-HER2 for osteosarcoma and other HER2-related indications Capital allocation focus remains on regulatory approval, priority review voucher (PRV) issuance and commercialization of OST-HER2 in osteosarcoma Previously disclosed $7.1M funding for OS therapies priced at $4.00/share provides cash runway into 2026 & precludes raises below $12.00 for 6 months Karim Galzahr appointed to OS Therapies Board of Directors OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted d

      1/29/25 9:22:00 AM ET
      $ADXS
      $OSTX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

      SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company's Board of Directors as an independent non-executive director, effective on March 31, 2021. Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America's best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biophar

      4/2/21 7:33:00 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    $ADXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Israel Biotech Fund I, L.P. bought 1,317,716 shares (SEC Form 4)

      4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)

      10/31/23 7:08:02 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care

    $ADXS
    Financials

    Live finance-specific insights

    See more
    • Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

      Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced further results from the Phase 2 (Part A) segment of the RINGSIDE study evaluating AL102 in desmoid tumors. The results were presented in a Poster Discussion Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 3. AL102 is a once-daily, po

      6/5/23 8:00:00 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

      REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the "Company," "New Ayala," "we," "us" or "our") (OTCQX:ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022. Management Commentary "We were pleased to close our previously announced merger in January 2023," said Kenneth A. Berlin, President and Chief Executive Officer of the Company. "Our immediate priorities include executing on Part B of the ongoing registration-enabling RINGSIDE study evaluating AL102 in desmoid tumors. We believe that AL102 has best in class potential and, if approved, m

      2/10/23 7:00:31 AM ET
      $ADXS
      Major Pharmaceuticals
      Health Care
    • Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary